Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 06:38 AM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Penny Stock Picks » Strong Buy: IGXT (MC $27 M) PDUFA Date on February 3 // 10 Dugs in Late Stage = 10+ Bagger

Thread Tools Search this Thread
Old 11-05-2013, 12:38 PM   Nav to Top  #1
Senior Trader
Biohero's Avatar
Join Date: Jan 2012
Location: Frankfurt
Posts: 305
Favorites: Aapl celg onxx
Rep Power: 118
Reputation: 36
Biohero is on a distinguished road
Default IGXT (MC $27 M) PDUFA Date on February 3 // 10 Dugs in Late Stage = 10+ Bagger

Brutally Undervalued Stock with tremendous upside potential...GL

2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .

NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
(According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)

IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
(According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)

Only 20 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA

Intelgenx (IGXT)

Market Cap : $27 M
Cash: $3 M

Burn-Rate : $2 M a year
Shares Out : 51 M ( 30 M shares are held by Investors )

IGXT´s Monster Pipeline :

Product ......Application......... Status of Development

INT0004/2006 Antidepressant -- US launch in 4Q 2012

INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014

INT0007/2006 Erectile Dysfunction -- NDA filing lin early 2014

INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing in early 2014

INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA under review by FDA

INT0020/2010 Insomnia -- in Pivotal Study

INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study

INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study

INT0030/2011 Animal health -- in Pivotal Study

INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study


Here is what the largest Shareholder (holds 6.2 Million shrs) says about IGXT

(Article about IGXT begins at page 8 )

Frankly, my target (first stated in July, 2011) of realizing $3-$8/share from IntelGenx over the life of the BIPES Fund has never seemed more reason able—the company has put in place more than enough building blocks to see that kind of sto ck price by the of 2016, as it becomes recognized as a world leader in the growing area of thin-film drug delivery and development. I like the fact that my $3 low end corresponds to the already-existing 1-year target of Ram Selvaraju, a well-respected and sophisticated Wall Street biotech analyst. If the PAR partnership blossoms into something special (whichis what I expect), the $5-$10 range becomes a real possibility.
Biohero is offline   Rate this post Yes | No Reply With Quote

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: PSDV (MC $80 M) PDUFA Date on October 17 for Blockbuster Drug + Low Float = 500% Pote Biohero US Stock Picks 6 09-17-2014 07:46 AM
Strong Buy: IGXT - FDA approval in 3Q (Mcap 31 M$) 10 Drugs in Pipeline !!! biotechmaster US Penny Stock Picks 20 11-11-2011 06:48 AM
Strong Buy: Blockbuster approval in 4Q11(Mcap 10 M) Cash 27 M biotechmaster US Penny Stock Picks 4 04-26-2011 04:58 PM
Strong Buy: Viagra Spray-NDA in 4Q11 (Mcap 5 M)= 10 BAGGER biotechmaster US Penny Stock Picks 2 04-07-2011 12:50 AM
Strong Buy: Blockbuster nearing Approval (Mcap 37 M$)=10 BAGGER EASILY !!! biotechmaster US Stock Picks 5 10-13-2010 05:37 AM

Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On